{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:06:13Z","timestamp":1779926773896,"version":"3.53.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-47698-x","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T10:46:22Z","timestamp":1775472382000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of delayed first radioiodine therapy on response evaluation in intermediate risk differentiated thyroid cancer"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5761-2337","authenticated-orcid":false,"given":"Medina-Ornelas","family":"Sevastian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Granados-Garc\u00eda","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vallejo-Casas","family":"Juan A","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"47698_CR1","unstructured":"Ferlay, J. et al. Global cancer observatory: Cancer today International Agency for Research on Cancer, Lyon, France, (2024). https:\/\/gco.iarc.who.int\/today. Accessed [4\/8\/2024]."},{"key":"47698_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen, B. R. et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1\u2013133 (2016).","journal-title":"Thyroid"},{"key":"47698_CR3","doi-asserted-by":"publisher","first-page":"509","DOI":"10.24875\/GMM.18003206","volume":"154","author":"S Medina-Ornelas","year":"2018","unstructured":"Medina-Ornelas, S., Garc\u00eda-P\u00e9rez, F. & Granados-Garc\u00eda, M. Impacto de la medicina nuclear en el diagn\u00f3stico y tratamiento del c\u00e1ncer diferenciado de tiroides. Gac. Med. Mex. 154, 509\u2013519. https:\/\/doi.org\/10.24875\/GMM.18003206 (2018).","journal-title":"Gac. Med. Mex."},{"issue":"Supp 1","key":"47698_CR4","first-page":"5","volume":"17","author":"M Granados-Garc\u00eda","year":"2018","unstructured":"Granados-Garc\u00eda, M. et al. Gu\u00eda de manejo del n\u00f3dulo tiroideo y del c\u00e1ncer diferenciado de tiroides de la Sociedad Mexicana de Oncolog\u00eda. Gac Mex Oncol. 17 (Supp 1), 5\u201331 (2018).","journal-title":"Gac Mex Oncol."},{"key":"47698_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-016-0404-6","volume":"17","author":"S Narayanan","year":"2016","unstructured":"Narayanan, S. & Colevas, A. D. Current standards in treatment of radioiodine refractory thyroid cancer. Curr. Treat. Options Oncol. 17, 30 (2016).","journal-title":"Curr. Treat. Options Oncol."},{"key":"47698_CR6","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1056\/NEJMoa2111953","volume":"386","author":"S Leboulleux","year":"2022","unstructured":"Leboulleux, S. et al. Thyroidectomy without radioiodine in patients with low-risk thyroid cancer. N. Engl. J. Med. 386, 923\u2013932 (2022).","journal-title":"N. Engl. J. Med."},{"key":"47698_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S2213-8587(18)30306-1","volume":"7","author":"HM Dehbi","year":"2019","unstructured":"Dehbi, H. M. et al. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): Long-term results of an open-label, non-inferiority randomised controlled trial. Lancet Diabetes Endocrinol. 7, 44\u201351 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"47698_CR8","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S2213-8587(18)30113-X","volume":"6","author":"M Schlumberger","year":"2018","unstructured":"Schlumberger, M. et al. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. The Lancet Diabetes & Endocrinology 6, 618\u2013626 (2018).","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"47698_CR9","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1210\/jc.2014-4332","volume":"100","author":"E Ruel","year":"2015","unstructured":"Ruel, E. et al. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. J. Clin. Endocrinol. Metab. 100, 1529\u20131536 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"47698_CR10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s00259-019-04479-1","volume":"47","author":"FA Verburg","year":"2020","unstructured":"Verburg, F. A. et al. Differentiated thyroid cancer patients potentially benefitting from postoperative I-131 therapy: A review of the literature of the past decade. Eur. J. Nucl. Med. Mol. Imaging 47, 78\u201383 (2020).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"47698_CR11","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1210\/jc.2011-2512","volume":"97","author":"C Schvartz","year":"2012","unstructured":"Schvartz, C. et al. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J. Clin. Endocrinol. Metab. 97, 1526\u20131535 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"47698_CR12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1200\/GO.20.00639","volume":"7","author":"R Riera","year":"2021","unstructured":"Riera, R. et al. Delays and disruptions in cancer health care due to COVID-19 pandemic: Systematic review. JCO Glob Oncol. 7, 311\u2013323 (2021).","journal-title":"JCO Glob Oncol."},{"key":"47698_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1053\/j.semnuclmed.2021.06.018","volume":"52","author":"F Giammarile","year":"2022","unstructured":"Giammarile, F. et al. Impact of COVID-19 on Nuclear Medicine Departments in Africa and Latin America. Semin. Nucl. Med. 52, 31\u201340 (2022).","journal-title":"Semin. Nucl. Med."},{"key":"47698_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.743310","volume":"12","author":"F Yu","year":"2021","unstructured":"Yu, F. et al. Delayed initial radioiodine adjuvant therapy does affect biochemical response in intermediate- to highRisk differentiated thyroid cancer. Front. Endocrinol. 12, 743310 (2021).","journal-title":"Front. Endocrinol."},{"key":"47698_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/cen.14950","volume":"99","author":"S Satapathy","year":"2023","unstructured":"Satapathy, S., Tupalli, A., Chandekar, K. R., Ballal, S. & Bal, C. Radioiodine versus no radioiodine outcomes in low-risk differentiated thyroid cancers: A propensity-score matched analysis. Clin. Endocrinol. (Oxf). 99, 483\u2013491 (2023).","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"47698_CR16","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1089\/thy.2020.0826","volume":"31","author":"SA Gulec","year":"2021","unstructured":"Gulec, S. A. et al. A joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on current diagnostic and theranostic approaches in the management of thyroid cancer. Thyroid 31, 1009\u20131019 (2021).","journal-title":"Thyroid"},{"key":"47698_CR17","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1007\/s00259-019-04472-8","volume":"46","author":"L Giovanella","year":"2019","unstructured":"Giovanella, L. et al. EANM practice guideline\/SNMMIprocedure standard for RAIU and thyroid scintigraphy. Eur. J. Nucl. Med. Mol. Imaging 46, 2514\u20132525 (2019).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"47698_CR18","doi-asserted-by":"crossref","first-page":"15N","DOI":"10.2967\/jnumed.121.262402","volume":"63","author":"AM Avram","year":"2022","unstructured":"Avram, A. M. et al. SNMMI procedure standard\/EANM practice guideline for nuclear medicine evaluation and therapy of differentiated thyroid cancer: Abbreviated version. J. Nucl. Med. 63, 15\u00a0N\u201335\u00a0N (2022).","journal-title":"J. Nucl. Med."},{"key":"47698_CR19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1089\/thy.2018.0597","volume":"29","author":"RM Tuttle","year":"2019","unstructured":"Tuttle, R. M. et al. Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: A joint statement from the American Thyroid Association, the European association of nuclear medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid 29, 461\u2013470 (2019).","journal-title":"Thyroid"},{"key":"47698_CR20","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1089\/thy.2016.0038","volume":"26","author":"RS Scheffel","year":"2016","unstructured":"Scheffel, R. S., Zanella, A. B., Dora, J. M. & Maia, A. L. Timing of radioactive iodine administration does not influence outcomes in patients with differentiated thyroid carcinoma. Thyroid 26, 1623\u20131629 (2016).","journal-title":"Thyroid"},{"key":"47698_CR21","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/cen.14039","volume":"91","author":"M Kim","year":"2019","unstructured":"Kim, M. et al. Impact of delayed radioiodine therapy in intermediate-\/high-risk papillary thyroid carcinoma. Clin. Endocrinol. (Oxf.) 91, 449\u2013455 (2019).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"47698_CR22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/MNM.0000000000000636","volume":"38","author":"JH Jeong","year":"2017","unstructured":"Jeong, J. H. et al. Clinical outcomes of low dose and high-dose postoperative radioiodine therapy in patients with intermediate -risk differentiated thyroid cancer. Nucl. Med. Commun. 38, 228\u2013233 (2017).","journal-title":"Nucl. Med. Commun."},{"key":"47698_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9020581","volume":"9","author":"AM G\u00f3mez-P\u00e9rez","year":"2020","unstructured":"G\u00f3mez-P\u00e9rez, A. M. et al. Efficacy of low-dose radioiodine ablation in low- and intermediate-risk differentiated thyroid cancer: A retrospective comparative analysis. J. Clin. Med. 9, 581 (2020).","journal-title":"J. Clin. Med."},{"key":"47698_CR24","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1002\/cam4.4607","volume":"11","author":"F Cheng","year":"2022","unstructured":"Cheng, F. et al. Delay of initial radioactive iodine therapy beyond 3 months has no effect on clinical responses and overall survival in patients with thyroid carcinoma: A cohort study and a meta-analysis. Cancer Med. 11, 2386\u20132396. https:\/\/doi.org\/10.1002\/cam4.4607 (2022).","journal-title":"Cancer Med."},{"key":"47698_CR25","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1089\/thy.2010.0178","volume":"20","author":"RM Tuttle","year":"2010","unstructured":"Tuttle, R. M. et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: Using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20, 1341\u20131349 (2010).","journal-title":"Thyroid"},{"key":"47698_CR26","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4158\/EP12244.RA","volume":"19","author":"J Klubo-Gwiezdzinska","year":"2013","unstructured":"Klubo-Gwiezdzinska, J. et al. Does an unsuccessful radioiodine treatment of differentiated thyroid cancer lead to radioiodine resistance? Endocr. Pract. 19, 212\u2013216 (2013).","journal-title":"Endocr. Pract."},{"key":"47698_CR27","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1001\/jama.2013.3190","volume":"309","author":"M Xing","year":"2013","unstructured":"Xing, M. et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309, 1493\u20131501 (2013).","journal-title":"JAMA"},{"key":"47698_CR28","doi-asserted-by":"publisher","first-page":"5970","DOI":"10.1158\/1078-0432.CCR-17-1183","volume":"23","author":"T Ibrahimpasic","year":"2017","unstructured":"Ibrahimpasic, T. et al. Genomic alterations in fatal forms of non-anaplastic thyroid cancer: Identification of MED12 and RBM10 as novel thyroid cancer genes associated with tumor virulence. Clin. Cancer Res. 23, 5970\u20135980 (2017).","journal-title":"Clin. Cancer Res."},{"key":"47698_CR29","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/cen.13413","volume":"87","author":"HG Vuong","year":"2017","unstructured":"Vuong, H. G., Altibi, A. M. A., Duong, U. N. P. & Hassell, L. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis. Clin. Endocrinol. (Oxf.) 87, 411\u2013417 (2017).","journal-title":"Clin. Endocrinol. (Oxf.)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47698-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47698-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47698-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:35:19Z","timestamp":1779924919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47698-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["47698"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-47698-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Hospital Angeles Lindavista (approval no. 020\/05\/MNI CEI\/1212\/19). Written informed consent was waived due to the retrospective nature of the study and the use of anonymized medical records for analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"During the preparation of this work, AI tools were used to improve the readability and language of the manuscript. Subsequently, the authors revised and edited the content produced by the AI tools as necessary and take full responsibility for the final content of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of artificial intelligence tools"}}],"article-number":"16528"}}